c46/ccr5/p140k lentiviral vector-transduced autologous hspcs
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 15, 2016 (NCT02343666)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- c46/ccr5/p140k lentiviral vector-transduced autologous hspcs
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02343666 | Phase 1 | Aug 15, 2016 | National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), University of Washington |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2016 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1